Lark can help you get back in the drivers seat of your benefits strategy, supporting smarter utilization, enabling better health outcomes, and up to 70% savings on medication costs.
Our first concern is your well-being
Retatrutide is an unlicensed investigational tri-agonist targeting GLP-1, GIP, and glucagon receptors
"I think the problem with giving this medication to people who really don't have an indication for it is they assume all the risks of it, plus the risk of weight regain, which may be adverse for their health," she says
By controlling the ingredients, you can ensure it contains no preservatives or additives such as carboxymethyl cellulose (cellulose gum) and mannitol as many pre-packaged B12 injection kits did
Its technically a dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, producing greater effects than GLP-1-only medications